Doxazosin Mesylate

Drug Usage Statistics, United States, 2007 - 2017

Number of Prescriptions Over Time (2007 - 2017)

Rank of Top Drugs Over Time

"Rank" refers to the frequency that a given medication is prescribed within a calendar year compared to all other medications. A rank of "4" would indicate that the medication was the fourth most commonly prescribed medication.

Year Rank Change
2007 112  4
2008 117  5
2009 129  12
2010 182  53
2011 119  63
2012 131  12
Year Rank Change
2013 148  17
2014 147  1
2015 156  9
2016 157  1
2017 150  7

Patient Out-Of-Pocket Cost Over Time (2007 - 2017)

"Out-of-pocket" cost refers to the payment made by the patient (either cash price or the copay amount). This value does not include reimbursement from a third party payer (eg, Medicare or private insurance) and does not represent the total drug cost.

Usage Statistics of Related Drugs

Drug Name Total Prescriptions (2017)
Carvedilol 22,974,069
Tamsulosin Hydrochloride 20,313,916
Doxazosin Mesylate (this drug) 4,313,778
Terazosin 2,936,434
Prazosin Hydrochloride 2,248,204
Alfuzosin Hydrochloride 1,606,983

Drug Synonyms

Drug synonyms are used during the sanitation and standardization process of "cleaning" the original data source (MEPS). Occassionally, brand names may be listed below that are no longer on the market or are very infrequently used.

Brand Name Synonyms
  • Cardura
  • Cardura XL
Generic Drug Synonyms and Salts
  • Doxazosin Mesylate

FDA Approval Information

Established Pharmacologic Class (EPC): alpha-Adrenergic Blocker
Initial FDA approval date: 11/2/1990
First FDA applicant: Rx
First dosage form: Tablet (oral)

Prescription data source: Medical Expenditure Panel Survey (MEPS) 2007-2017. Agency for Healthcare Research and Quality (AHRQ), Rockville, MD. ClinCalc DrugStats Database version 20.1. Read more about the ClinCalc DrugStats database.


Related Links

Follow Us!

New and Popular


Open Menu

Cite This Page

Show AMA citation

RxHero - Gamified learning for the Top 250 Drugs
©2020 - ClinCalc LLC. All rights reserved.
Disclaimer - Privacy Policy - Contact Us
Updated Jul 19, 2018
Back to Top